Ülke: Birleşik Krallık
Dil: İngilizce
Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)
Cisatracurium besilate
Aspen Pharma Trading Ltd
M03AC11
Cisatracurium besilate
5mg/1ml
Solution for injection
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 15010500; GTIN: 5010706005778
- 1 - [ASPEN LOGO] INFORMATION FOR THE PHYSICIAN NIMBEX CISATRACURIUM PLEASE REFER TO THE SUMMARY OF PRODUCT CHARACTERISTICS (SPC) FOR FURTHER DETAILS ON THIS PRODUCT. TRADE NAME OF THE MEDICINAL PRODUCT Nimbex 2 mg/ml solution for injection/infusion Nimbex Forte 5 mg/ml solution for injection/infusion QUALITATIVE AND QUANTITATIVE COMPOSITION Nimbex 2 mg/ml, solution for injection: Cisatracurium 2 mg as cisatracurium besilate 2.68 mg per 1 ml one ampoule of 10 ml contains 20 mg of cisatracurium one ampoule of 25 ml contains 50 mg of cisatracurium Nimbex Forte 5 mg/ml, solution for injection: Cisatracurium 5 mg as cisatracurium besilate 6.70 mg per 1 ml one vial of 30 ml contains 150 mg of cisatracurium PHARMACEUTICAL FORM Solution for injection/infusion. Colourless to pale yellow or greenish yellow solution. Practically free from visible particulate matter. THERAPEUTIC INDICATIONS Nimbex is indicated for use during surgical and other procedures in adults and children aged 1 month and over. Nimbex is also indicated for use in adults requiring intensive care. Nimbex can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. POSOLOGY AND METHOD OF ADMINISTRATION Nimbex should be only administered by or under the supervision of anaesthetists or other clinicians who are familiar with the use and action of neuromuscular blocking agents. Facilities for tracheal intubation, and maintenance of pulmonary ventilation and adequate arterial oxygenation have to be available. Please note that Nimbex should not be mixed in the same syringe or administered simultaneously through the same needle as propofol injectable emulsion or with alkaline solutions such as sodium thiopentone. Nimbex contains no antimicrobial preservative and is intended for single patient use. - 2 - MONITORING ADVICE As with other neuromuscular blocking agents, monitoring of neuromuscular function is recommended during the use of Ni Belgenin tamamını okuyun
OBJECT 1 NIMBEX FORTE INJECTION 5MG/ML Summary of Product Characteristics Updated 04-Aug-2017 | Aspen 1. Name of the medicinal product Nimbex Forte 5mg/ml solution for injection/infusion. 2. Qualitative and quantitative composition Cisatracurium 5mg as cisatracurium besilate 6.70mg per 1ml One vial of 30ml contains 150mg of cisatracurium For the full list of excipients, see Section 6.1. 3. Pharmaceutical form Solution for injection/infusion. Colourless to pale yellow or greenish yellow solution. Practically free from visible particulate matter. 4. Clinical particulars Nimbex is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration. 4.1 Therapeutic indications Nimbex is indicated for use during surgical and other procedures in adults and children aged 1 month and over. Nimbex is also indicated for use in adults requiring intensive care. Nimbex can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. 4.2 Posology and method of administration Nimbex should only be administered by or under the supervision of anaesthetists or other clinicians who are familiar with the use and action of neuromuscular blocking agents. Facilities for tracheal intubation, and maintenance of pulmonary ventilation and adequate arterial oxygenation have to be available. Please note that Nimbex should not be mixed in the same syringe or administered simultaneously through the same needle as propofol injectable emulsion or with alkaline solutions such as sodium thiopentone. (see section 6.2). Nimbex contains no antimicrobial preservative and is intended for single patient use. MONITORING ADVICE As with other neuromuscular blocking agents, monitoring of neuromuscular function is recommended during the use of Nimbex in order to individualise dosage requirements. USE BY INTRAVENOUS BOLUS INJECTION DOSAGE IN ADULTS TRACHEAL INTUBATION. The recommended intubation dose of Belgenin tamamını okuyun